What Happens in June: Your Guide to the DEA Cannabis Rescheduling Hearings

The DOJ's April 23 order reclassifying state-licensed medical marijuana to Schedule III was a historic first step — but the bigger fight is still ahead. On June 29, 2026, the Drug Enforcement Administration will open expedited administrative hearings to consider the broader rescheduling of all marijuana from Schedule I to Schedule III. Here's everything you need to know about what could become the most consequential drug policy proceeding in modern American history.

Why the June Hearings Matter More Than the April Order

The April 23 executive action was deliberately narrow in scope. It moved two specific categories of marijuana into Schedule III: FDA-approved drug products containing cannabis and items regulated under a qualifying state medical marijuana license. Recreational cannabis, which accounts for the majority of legal sales across 24 states, remained untouched.

The June hearings represent the next and far more ambitious phase. If the DEA's administrative law judge recommends full rescheduling — and the agency accepts — every form of marijuana would shift from Schedule I to Schedule III, regardless of whether it's sold in a medical or adult-use market. That single change would reshape the entire industry overnight.

The Timeline: What Happens and When

According to the DOJ's order, the proceedings will follow an accelerated timeline designed to reach a resolution before the end of summer:

June 29, 2026: Hearings officially open before a DEA administrative law judge. The expedited format means both sides will present evidence, call witnesses, and cross-examine testimony in rapid succession.

July 15, 2026: Target date for hearings to conclude. The compressed schedule — roughly two and a half weeks — signals the administration's desire for speed over drawn-out deliberation.

Late Summer / Early Fall 2026: The administrative law judge issues a recommended decision. The DEA Administrator then reviews the recommendation and decides whether to accept, modify, or reject it.

If accepted without legal challenges, a final rule could land in the Federal Register by fall 2026, though lawsuits are virtually guaranteed to extend that timeline.

Who Will Testify — and Who Will Object

The hearing format allows for public participation, and both sides are already preparing their cases.

In Favor of Rescheduling: Expect testimony from cannabis researchers who have long argued that Schedule I's restrictions have strangled scientific inquiry. Medical professionals, patient advocacy groups, state regulators, and industry representatives will likely present evidence that marijuana has accepted medical use — the core criterion that differentiates Schedule I from Schedule III.

Against Rescheduling: Smart Approaches to Marijuana (SAM), the most prominent anti-legalization organization in the country, announced within hours of the April 23 order that it would "take legal action immediately." SAM and aligned groups are expected to argue that rescheduling will normalize recreational use, increase youth access, and undermine public health efforts.

Law enforcement organizations, certain public health groups, and potentially the pharmaceutical industry may also weigh in, though their positions are less predictable.

What Schedule III Actually Means in Practice

The practical differences between Schedule I and Schedule III are substantial. Schedule I substances are defined as having "no currently accepted medical use" and "a high potential for abuse." Schedule III drugs, by contrast, are recognized as having moderate to low dependence potential and accepted medical applications. Think ketamine, anabolic steroids, and Tylenol with codeine.

For cannabis, the shift would mean several immediate changes. Research access would expand dramatically, as scientists would no longer need the onerous Schedule I research license that has bottlenecked cannabis studies for decades. The IRS Section 280E tax burden would lift across the entire industry — not just medical operators — saving businesses billions in previously undeductable expenses. And the broader financial ecosystem, including banking, insurance, and payment processing, would face significantly less federal risk in serving cannabis companies.

However, Schedule III does not equal legalization. Cannabis would remain a controlled substance, subject to DEA oversight, prescription requirements at the federal level, and ongoing regulatory frameworks. Interstate commerce would still face hurdles, and the patchwork of state laws would continue to govern day-to-day operations.

Legal Challenges Are Already Brewing

Multiple legal challenges are expected regardless of the hearing's outcome. If the DEA moves forward with full rescheduling, opponents will likely challenge the scientific basis for the determination, argue that the process was politically motivated, or seek injunctions to delay implementation.

Conversely, if the hearings result in a narrower outcome — rescheduling only certain formulations or maintaining restrictions on recreational products — the cannabis industry and advocacy organizations will push for broader relief through additional legal and legislative channels.

The SAFER Banking Act, reintroduced in Congress this week with 14 bipartisan Senate cosponsors, represents a parallel legislative track that could provide cannabis businesses with banking protections regardless of the scheduling outcome.

What Consumers and Businesses Should Do Now

For cannabis consumers, the June hearings won't change day-to-day access in legal states. Your dispensary will still be open, your products will still be available, and your state's laws still govern what you can buy and possess.

For cannabis businesses, the calculus is different. Operators should be working with tax professionals now to understand how 280E relief would affect their books, preparing financial statements that reflect deductible expenses, and considering how improved banking access could reshape their capital structure.

For investors, the hearings represent both opportunity and risk. The initial market rally following the April 23 announcement — the MSOS ETF surged 19.39% before pulling back — showed that Wall Street is watching closely but remains cautious about the scope of reform.

The Bigger Picture

The June hearings aren't happening in a vacuum. Nine states have cannabis reform measures filed for the November 2026 ballot, including both legalization initiatives and unprecedented repeal efforts. The political landscape is shifting rapidly, and the DEA hearings will likely influence ballot campaigns in both directions.

Whether you're a patient, a consumer, a business owner, or simply someone who follows drug policy, June 29 is a date worth marking on your calendar. The outcome won't just determine marijuana's legal classification — it could define the trajectory of American cannabis policy for a generation.

Related reading: The DOJ's April 23 Schedule III order — full breakdown · How cannabis stocks reacted to rescheduling news · Why 280E repeal is the industry's biggest tax win

Explore cannabis news, find dispensaries, and join the community at Budpedia.